•  
  •  
  •  
  •  

2026-07-19 23:39:19

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Kotak Mahindra Bank Group Posts Strong Q1 FY27 Performance: Consolidated Net Profit Rises 23% Year-on-Year to ₹5,480 Crore driven by Retail and Subsidiary Strengths
  • Punjab National Bank Scripting Financial Excellence: Net Profit Skyrockets 213.6% in Q1 FY27 Driven by Asset Quality Milestones and Digital Edge
  • Axis Bank Group Delivers Stellar Q1 FY27 Performance: Consolidated Net Profit Climbs to ₹7,632 Crore and Advances Surge 19% Y-o-Y
  • Reliance Industries Starts New Fiscal on a High: Q1 FY27 Revenue Surges 24.5% to ₹3.4 Lakh Crore as Jio and O2C Units Drive Record Earnings
  • Chembond Material Technologies Consolidated Net Profit Surges 43.5% to ₹572.6 Lakh in Q1 FY27; Revenue Tops ₹7,200 Lakh

Keywords Selected:  Biocon

Research

  • Biocon Limited - Generics & research grow; biosimilar stagnates - ICICI Securities
  • Q4FY22 Result Update – Biocon Ltd - ICICI Direct
  • Biocon - Q4FY22 First Cut - ICICI Direct
  • Q3FY22 Result Update - Biocon Ltd - ICICI Direct
  • Q2FY22 Result Update - Biocon Ltd - ICICI Direct

Stock Report

  • Biocon Reinforces Commitment to Diabetes Care in Malaysia as Partner Duopharma Biotech Secures Insulin Tenders
  • Biocon Pharma Limited Receives Health Canada Approval for Micafungin for Injection, USP, 50 MG and 100 MG
  • Biocon Ltd recommends final dividend of Rs. 0.50
  • Biocon Ltd reports consolidated PAT of Rs. 125.9 crores in Q4 FY2025-26
  • Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™, Biosimilars to Prolia® and Xgeva®
  • Biocon Pharma Ltd receives U.S. FDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026
  • Biocon obtains approval for weight management drug, Liraglutide, in the United States
  • Fitch Ratings Revises Biocon Biologics Outlook from 'Stable' to 'Positive'
  • Biocon Ltd signs out-licensing agreement with Ajanta to market Semaglutide in 26 countries
  • Ajanta signs in-licensing agreement with Biocon for marketing Semaglutide in 26 countries
  • Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
  • Biocon Ltd receives EIR from USFDA with VAI status for Cranbury facility
  • Biocon Biologics Recognized as Asia IP Elite for 2025 by IAM
  • Biocon Limited launches its Glucagon-like Peptide-1, Liraglutide, in the Netherlands
  • Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide
  • Biocon Ltd to integrate Biocon Biologics Ltd to create a Unified Global Biopharmaceutical Leader
  • Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Rest of the World
  • Biocon Biologics' Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated
  • Biocon Pharma Ltd receives approval from USFDA for its ANDA
  • Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V., a Biosimilar to Stelara®
  • Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine
  • Biocon Limited updates on GMP inspection by USFDA at its Cranbury, New Jersey facility
  • Biocon Pharma Ltd in partnership with Carnegie Pharmaceuticals LLC receives USFDA tentative approval for Rifaximin Tablets

Latest Post

  • Kotak Mahindra Bank Group Posts Strong Q1 FY27 Performance: Consolidated Net Profit Rises 23% Year-on-Year to ₹5,480 Crore driven by Retail and Subsidiary Strengths
  • Punjab National Bank Scripting Financial Excellence: Net Profit Skyrockets 213.6% in Q1 FY27 Driven by Asset Quality Milestones and Digital Edge
  • Axis Bank Group Delivers Stellar Q1 FY27 Performance: Consolidated Net Profit Climbs to ₹7,632 Crore and Advances Surge 19% Y-o-Y
  • Reliance Industries Starts New Fiscal on a High: Q1 FY27 Revenue Surges 24.5% to ₹3.4 Lakh Crore as Jio and O2C Units Drive Record Earnings
  • Chembond Material Technologies Consolidated Net Profit Surges 43.5% to ₹572.6 Lakh in Q1 FY27; Revenue Tops ₹7,200 Lakh


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025